EP1139754A4 - 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy - Google Patents

3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Info

Publication number: EP1139754A4
Authority: EP; European Patent Office
Prior art keywords: heteroarylidenyl; protein kinase; kinase activity; cancer chemotherapy; modulating protein
Prior art date: 1998-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP99966725A

Other languages

German (de)

French (fr)

Other versions

EP1139754A1 (en

Inventor

Peter J Langecker

Laura Kay Shawver

Peng Cho Tang

Li Sun

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sugen LLC

Original Assignee

Sugen LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-31

Filing date

1999-12-30

Publication date

2002-12-18

1999-12-30 Application filed by Sugen LLC filed Critical Sugen LLC

2001-10-10 Publication of EP1139754A1 publication Critical patent/EP1139754A1/en

2002-12-18 Publication of EP1139754A4 publication Critical patent/EP1139754A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

EP99966725A 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy Withdrawn EP1139754A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11431398P	1998-12-31	1998-12-31
US114313P		1998-12-31
PCT/US1999/031232 WO2000038519A1 (en)	1998-12-31	1999-12-30	3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Publications (2)

Publication Number	Publication Date
EP1139754A1 EP1139754A1 (en)	2001-10-10
EP1139754A4 true EP1139754A4 (en)	2002-12-18

Family

ID=22354480

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99966725A Withdrawn EP1139754A4 (en)	1998-12-31	1999-12-30	3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Country Status (10)

Country	Link
EP (1)	EP1139754A4 (en)
JP (1)	JP2002533360A (en)
KR (1)	KR20010108063A (en)
CN (1)	CN1356872A (en)
AU (1)	AU760964B2 (en)
BR (1)	BR9916735A (en)
CA (1)	CA2357042A1 (en)
IL (1)	IL143920A0 (en)
MX (1)	MXPA01006742A (en)
WO (1)	WO2000038519A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6569868B2 (en)	1998-04-16	2003-05-27	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
PT1233943E (en) *	1999-11-24	2011-09-01	Sugen Inc	Ionizable indolinone derivatives and their use as ptk ligands
US6878733B1 (en)	1999-11-24	2005-04-12	Sugen, Inc.	Formulations for pharmaceutical agents ionizable as free acids or free bases
NZ520640A (en) *	2000-02-15	2005-04-29	Upjohn Co	Pyrrole substituted 2-indolinone protein kinase inhibitors
PL363110A1 (en) *	2000-02-28	2004-11-15	Aventis Pharma S.A.	A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
TWI270545B (en)	2000-05-24	2007-01-11	Sugen Inc	Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en)	2000-06-02	2001-12-13	Sugen, Inc.	Indolinone derivatives as protein kinase/phosphatase inhibitors
BRPI0207961B8 (en)	2001-03-14	2021-05-25	Bristol Myers Squibb Co	use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds.
AU2002303892A1 (en)	2001-05-30	2002-12-09	Jingrong Cui	5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR038957A1 (en) *	2001-08-15	2005-02-02	Pharmacia Corp	COMBINATION THERAPY FOR CANCER TREATMENT
WO2003035619A1 (en) *	2001-10-25	2003-05-01	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2003035616A2 (en) *	2001-10-25	2003-05-01	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2003035614A2 (en) *	2001-10-25	2003-05-01	Merck & Co., Inc.	Tyrosine kinase inhibitors
MXPA04004804A (en) *	2001-11-21	2005-02-17	Sugen Inc	Pharmaceutical formulations comprising indolinone derivatives.
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
RU2316554C2 (en)	2001-12-27	2008-02-10	Тереванс, Инк.	Derivatives of indoline used as protein kinase inhibitors
EP1515680A4 (en) *	2002-06-25	2005-09-21	Wyeth Corp	Use of thio-oxindole derivatives in treatment of skin disorders
BR0312054A (en) *	2002-06-25	2005-10-18	Wyeth Corp	Use of thiooxyindole derivatives in the preparation of medicaments useful in the treatment of hormone related conditions, and pharmaceutical kit
BRPI0313165B8 (en)	2002-08-02	2021-05-25	Ab Science	2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en)	2002-08-02	2013-05-28	Ab Science	2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004045617A1 (en) *	2002-11-15	2004-06-03	Warner-Lambert Company Llc	Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
PL1684750T3 (en)	2003-10-23	2010-10-29	Ab Science	2-aminoaryloxazole compounds as tyrosine kinase inhibitors
CN100432071C (en) *	2004-11-05	2008-11-12	中国科学院上海药物研究所	Substituted 1H-indole-2-ketone compound and its preparation method and uses
CA2603826C (en)	2005-04-04	2013-03-12	Ab Science	Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US8246966B2 (en)	2006-08-07	2012-08-21	University Of Georgia Research Foundation, Inc.	Trypanosome microsome system and uses thereof
WO2008066755A2 (en)	2006-11-22	2008-06-05	University Of Georgia Research Foundation, Inc.	Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
PT2780011T (en) *	2011-11-11	2018-05-14	Lilly Co Eli	Combination therapy for ovarian cancer
JP7041515B2 (en)	2015-01-08	2022-03-24	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	Factors and cells that provide bone, bone marrow, and cartilage induction
MD3288940T2 (en)	2015-04-29	2021-08-31	Janssen Pharmaceutica Nv	Azabenzimidazoles and their use as ampa receptor modulators
CN105585558A (en) *	2015-12-15	2016-05-18	贵州大学	Double-alkoxy pyrimidine jointing 3-ethylenic-bond-oxoindole derivative and preparing method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998007695A1 (en) *	1996-08-23	1998-02-26	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease

1999
- 1999-12-30 BR BR9916735-2A patent/BR9916735A/en not_active IP Right Cessation
- 1999-12-30 JP JP2000590484A patent/JP2002533360A/en not_active Withdrawn
- 1999-12-30 IL IL14392099A patent/IL143920A0/en unknown
- 1999-12-30 CA CA002357042A patent/CA2357042A1/en not_active Abandoned
- 1999-12-30 AU AU22215/00A patent/AU760964B2/en not_active Ceased
- 1999-12-30 KR KR1020017008453A patent/KR20010108063A/en not_active Application Discontinuation
- 1999-12-30 CN CN99816376A patent/CN1356872A/en active Pending
- 1999-12-30 WO PCT/US1999/031232 patent/WO2000038519A1/en not_active Application Discontinuation
- 1999-12-30 EP EP99966725A patent/EP1139754A4/en not_active Withdrawn
- 1999-12-30 MX MXPA01006742A patent/MXPA01006742A/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998007695A1 (en) *	1996-08-23	1998-02-26	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number	Publication date
BR9916735A (en)	2001-09-25
AU2221500A (en)	2000-07-31
KR20010108063A (en)	2001-12-07
AU760964B2 (en)	2003-05-22
WO2000038519A1 (en)	2000-07-06
EP1139754A1 (en)	2001-10-10
MXPA01006742A (en)	2004-04-21
CN1356872A (en)	2002-07-03
CA2357042A1 (en)	2000-07-06
IL143920A0 (en)	2002-04-21
JP2002533360A (en)	2002-10-08

Legal Events

Date	Code	Title	Description
2001-08-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-10-10	17P	Request for examination filed	Effective date: 20010730
2001-10-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-10-10	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-03-13	RIN1	Information on inventor provided before grant (corrected)	Inventor name: SUN, LI Inventor name: TANG, PENG, CHO Inventor name: SHAWVER, LAURA, KAY Inventor name: LANGECKER, PETER, J.
2002-12-18	A4	Supplementary search report drawn up and despatched	Effective date: 20021107
2002-12-18	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-12-18	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 01N 43/38 A, 7A 61K 31/40 B, 7A 61K 31/505 B
2003-10-29	17Q	First examination report despatched	Effective date: 20030915
2004-06-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2004-08-04	18D	Application deemed to be withdrawn	Effective date: 20040126

Publication	Publication Date	Title
EP1139754A4 (en)	2002-12-18	3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
IL146094A0 (en)	2002-07-25	Diaminothiazoles and their use for inhibiting protein kinases
HUP0200403A2 (en)	2002-06-29	Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
EP1066286A4 (en)	2004-02-11	Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
ZA989249B (en)	2000-04-10	Heteroaromatic compounds and their use in medicine.
ZA9810219B (en)	2000-06-22	Benzothiazole protein tyrosine kinase inhibitors.
HRP980010B1 (en)	2002-06-30	Quinoline and quinazoline compounds useful in therapy
GB2337200B (en)	2000-07-26	Smoking substance for use in therapy
EP1005480A4 (en)	2002-10-09	Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
IL114418A0 (en)	1995-10-31	Tumor necrosis factor receptor-II associated protein kinase and methods for its use
IL206604A0 (en)	2011-07-31	Transmembrane protein expressed in prostate cancer
HUP0103079A2 (en)	2001-12-28	Modulating multiple lineage kinase proteins
GB9816761D0 (en)	1998-09-30	Herpesvirus preparations and their uses
ZA985999B (en)	1999-04-20	Protein kinases and uses thereof
AU4686299A (en)	2000-01-05	Nek-related and bub1-related protein kinases
AU2113899A (en)	1999-08-16	Human protein kinase molecules
AU1456899A (en)	1999-06-15	Human protein kinase and kinase inhibitors
AU6111800A (en)	2001-02-13	26 human prostate and prostate cancer associated proteins
IL147345A0 (en)	2002-08-14	Drosphila recombination- associated protein and methods for use
GB9803399D0 (en)	1998-04-15	Protein kinase c
AU2001279090A1 (en)	2002-03-04	Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
AU4328399A (en)	2000-01-05	Nucleic acid-cobalamin complexes and their use in gene therapy
ZA987206B (en)	1999-02-12	Cycline-dependent protein kinase-activating kinase and its uses
AU5781900A (en)	2001-07-16	3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
AU1464399A (en)	1999-06-15	Reagent for tumor therapy and/or imaging